TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.

NCT07009184 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

HER2 Positive Solid Tumor

Interventions

DRUG: [111In]In-DOTA-TCO-trastuzumab
DRUG: Small molecule tetrazine trigger component

Sponsor

Radboud University Medical Center

Collaborators

[object Object]